Tacrolimus in Renal Transplantation

Kidney Transplantation

Volumn , Issue , 2008, Pages 259-276

  Basu, Amit ^a   Shapiro, Ron ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954565206     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3343-1.50021-9     Document Type: Chapter

References (148)

1. Ahsan N, Hricik D, Matas A, for the Steroid Withdrawal Study Group, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: a prospective randomized study. Transplantation 1999, 68:1865.
2. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at two years. Transplantation 2001, 72:245.
3. Armenti VT, Corscia LA, McGrory CH, et al. National Transplantation Pregnancy Registry looks at outcomes with Neoral and tacrolimus. Nephrol News Issues 2000, 14:S11.
4. Artz MA, Boots JMM, Ligtenberg G, et al. Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels. Transplant Proc 2002, 34:1793.
5. Astellas, Inc: Prograf prescribing information (US). Available at:. Accessed January 22, 2007. http://www.prograf.com/pdf/prograf_full_prescribing_information.pdf.
6. Augustine JJ, Chang PC, Knauss TC, et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006, 81:1004.
7. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NL, et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004, 77:1199.
8. Baldwin D, Duffin K Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004, 77:1009.
9. Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: one year results of a large multicenter trial. Transplantation 2004, 77:1221.
10. Boots J, Van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002, 13:221.
11. Borrows R, Chan K, Loucaidou M, et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 2005, 80:125.
12. Braun F, Schutz E, Peters B, et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc 2001, 33:2127.
13. Bresnahan BA, Cherikh WS, Cheng Y, et al. Short-term benefit of tacrolimus versus cyclosporine therapy after renal transplantation: an analysis of UNOS/OPTN database. Am J Transplant 2003, 3(Suppl 5):462. (abstract 1213).
14. Buell JF, Kulkarni S, Grewal HP, et al. Early corticosteroid cessation at one week following kidney transplant under tacrolimus and mycophe-nolate mofetil (MMF) immunosuppression, three-year follow up. Transplantation 2000, 69:S134. (abstract).
15. Burke GW, Ciancio G, Figueiro J, et al. Can acute rejection be prevented in SPK transplantation?. Transplant Proc 2002, 34:1913.
16. Burke GW, Kaufman DB, Millis JM, et al. Prospective randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004, 77:1269.
17. Calconi G, Vianello A One-year follow up of a large European trial comparing dual versus triple tacrolimus-based immunosuppressive regimens following renal transplantation: Italian and Spanish Tacrolimus Study Group. Transplant Proc 2001, 33:1021.
18. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998, 351:1701.
19. Calne R, Moffatt SD, Friend PJ, et al. Campath-1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999, 68:1613.
20. Campistol JM, Grinyo JM Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001, 71:S542.
21. Cantarovich D, Rostaing L, Mourad G The combination of daclizumab, tacrolimus and MMF is an effective and safe steroid-free immunosuppressive regimen after renal transplantation: results of a large multicenter trial. Nephrol Dial Transplant 2003, 18(Suppl 4):788.
22. Chang R-WS, Snowden S, Palmer A, et al. European randomized trial of dual versus triple tacrolimus-based regimens for control of acute rejection in renal allograft recipients. Transpl Int 2001, 14:384.
23. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically-relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002, 41:813.
24. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005, 80:457.
25. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006, 81:845.
26. Ciancio G, LoMonte A, Buscemi G, et al. Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation. Transpl Int 2000, 13:S191.
27. Ciancio G, Sageshima J, Burke GW, et al: Evaluation of a randomized trial of three induction antibodies in deceased donor (DD) renal transplantation at 18 months follow-up. Program and abstracts of the World Transplant Congress 2006, Boston, July 22-27, 2006 (Abstract 919).
28. Coley KC, Verrico MM, McNamara DM, et al. Lack of tacrolimus-induced cardiomyopathy. Ann Pharmacother 2001, 35:985.
29. Dharnidharka VR, Ho P-L, Stablein DM, et al. Mycophenolate, tacrolimus and posttransplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002, 6:396.
30. Donahoo WT, Kosmiski LA, Eckel RH Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am 1998, 27:677.
31. Dudley CRK Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion to tacrolimus in renal transplant recipients. Transplant Proc 2001, 33:1034.
32. Ferrarris JR, Tambutti ML, Cardori RL, et al. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection. Transplantation 2004, 77:532.
33. Filler G, Womiloju T, Feber J, et al. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005, 5:2005.
34. Filler G, Webb NJA, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporine microemulsion. Pediatr Transplant 2005, 9:498.
35. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005, 5:3009.
36. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004, 4:1776.
37. Foster CE, Philosophe B, Schweitzer EJ, et al. A decade of experience with renal transplantation in African-Americans. Ann Surg 2002, 236:794.
38. Friese CE, Sang-Mo K, Feng S, et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk pancreas-kidney transplantation. Arch Surg 2003, 138:1121.
39. Fung JJ Tacrolimus and transplantation: a decade in review. Transplantation 2004, 77:S41.
40. Garcia I Efficacy and safety of dual versus triple tacrolimus-based therapy in kidney transplantation: two year follow up. Transplant Proc 2002, 34:1638.
41. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus and mycophenolate mofetil or azathioprine versus cyclosporine and mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003, 75:2045.
42. Gonwa T, Mendez R, Yang HC, for the Prograf Study Group, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at six months. Transplantation 2003, 75:1213.
43. Gourishankar S, Hunsicker LG, Jhangri GS, et al. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003, 14:2387.
44. Gruessner RWG, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996, 61:261.
45. Gruessner AC, Sutherland DER Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and International Pancreas Transplant Registry as of October 2002. Clinical Transplants 2002 2003, 41. UCLA Tissue Typing Laboratory, Los Angeles. J.M. Cecka, P.I. Terasaki (Eds.).
46. Gruessner AC, Sutherland DER, Dunn DL, et al. Pancreas after kidney transplants in post-uremic patients with Type I diabetes mellitus. J Am Soc Nephrol 2001, 12:2490.
47. Gruessner RW, Sutherland DE, Najarian JS, et al. Solitary pancreas transplantation for non-uremic patients with labile insulin-dependent diabetes mellitus. Transplantation 1997, 64:1572.
48. Gruessner RWG, Sutherland DER, Parr E, et al. A prospective, randomized open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with six months' follow up. Transplant Proc 2001, 33:1663.
49. Halloran P, Ahsan N, Johnson C, et al. Three-year follow up of randomized multicenter kidney transplant study comparing tacrolimus (TAC) + azathioprine (AZA) versus cyclosporine modified (CsA) + mycophenolate mofetil (MMF) versus TAC + MMF. Am J Transplant 2001, 1(Suppl 1):405.
50. Hamdy AF, El-Agroudy AE, Bakr MA, et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005, 5:2531.
51. Hardinger KL, Bolul DL, Schnitzer MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with Thymoglobulin in renal transplant recipients. Transplantation 2005, 80:41.
52. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 1996, 61:1161.
53. Heisel O, Heisel R, Batshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583.
54. Hricik DE, Anton HA, Knauss TC, et al. Outcomes of African-American kidney transplant recipients treated with sirolimus, tacrolimus and corticosteroids. Transplantation 2002, 74:189.
55. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on post-transplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991, 51:374.
56. Humar A, Parr E, Drangstveit MG, et al. Steroid withdrawal in pancreas transplant recipients. Clin Transpl 2000, 14:75.
57. Jain AB, Shapiro R, Scantlebury VP, et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation 2004, 77:897.
58. Jamieson NV Adult small intestinal transplantation in Europe. Acta Gastroenterol Belg 1999, 62:239.
59. Jensik SC, for the FK506 Kidney Transplant Study Group Tacrolimus (FK506) in kidney transplantation: three-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc 1998, 30:1216.
60. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000, 69:834.
61. Jordan ML, Chakrabarti P, Luke P, et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation 2000, 69:265.
62. Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus rescue therapy for renal allograft rejection-five years' experience. Transplantation 1997, 63:223.
63. Jordan ML, Naraghi RL, Shapiro R, et al. Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc 1997, 29:306.
64. Jordan ML, Shapiro R, Jensen CWB, et al. FK506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 1991, 23:3078.
65. Kaibori M, Sakitani K, Ota M, et al. Immunosuppressant FK506 inhibits inducible nitric oxide synthetase gene expression at a step of the NKκB activation in rat hepatocytes. J Hepatol 1999, 30:1138.
66. Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-an interim analysis. Am J Transplant 2005, 5:1529.
67. Kaplan B, Schold JD, Meier-Kriesche H-U Long-term graft survival with Neoral and tacrolimus: A paired kidney analysis. J Am Soc Nephrol 2003, 14:2980.
68. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178.
69. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 2005, 5:2539.
70. Kaufman DB, Leventhal JR, Gallon LG, et al. Technical and immunologic progress in simultaneous pancreas-kidney transplantation. Surgery 2002, 132:545.
71. Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation. Transplantation 2002, 73:169.
72. Klein IH, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002, 73:732.
73. Klinger M, Vitko S, Karja S, et al. Large prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation. Nephrol Dial Transplant 2003, 18(Suppl 4):788.
74. Kulkarni S, Kopelan A, Woodle ES Tacrolimus therapy in renal transplantation. Kidney Transplantation: Principles and Practice 2001, 251-262. Saunders, Philadelphia. P.J. Morris (Ed.).
75. Kumar MSA, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005, 80:807.
76. Kur F, Reichenspurner H, Meiser BM, et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Thorac Cardiovasc Surg 1999, 47:174.
77. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005, 137:364.
78. Land W, Malaise J, Sandberg J, et al. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at one year of a large multicenter trial. Transplant Proc 2002, 34:1911.
79. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006, 6:514.
80. Legendre C, Thervet E, Skhiri H, et al. Histological features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998, 65:1506.
81. Ligtenberg G, Hené RJ, Blankestijn PJ, et al. Cardiovascular risk factors in renal transplant patients: cyclosporine A versus tacrolimus. J Am Soc Nephrol 2001, 12:368.
82. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001, 69:24.
83. Mann M, Tanabe K, Tokumoto T, et al. Impact of tacrolimus on hyper-lipidemia after renal transplantation: a Japanese single center experience. Transplant Proc 2000, 32:1736.
84. Margreiter R, for the European Tacrolimus versus Ciclosporine Microemulsion Renal Transplant Study Group Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: a randomized multicenter study. Lancet 2002, 359:741.
85. Mayer AD Chronic rejection and graft half-life: five-year follow up of the European tacrolimus multicenter renal study. Transplant Proc 1998, 34:1491.
86. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997, 64:436.
87. Meier-Kriesche H-U, Hricik DE Are we ready to give up on calcineurin inhibitors?. Am J Transplant 2006, 6:445.
88. Meier-Kriesche H-U, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005, 5:2273.
89. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation; importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999, 18:143.
90. Migita K, Eguchi T, Kawabe Y, et al. FK506 potentiates steroid-induced T-cell apoptosis. Transplantation 1997, 64:365.
91. Miller J, Burke GW, Ciancio G, et al. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection. Am J Transplant 2003, 3(Suppl 5):465. (abstract 1222).
92. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000, 63:977.
93. Montori VM, Basu A, Erwin PJ, et al. Post-transplantation diabetes: a systematic review of the literature. Diabetes Care 2002, 25:583.
94. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326.
95. Neu AM, Ho PL, Fine RN, et al. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003, 7:217.
96. Neylan JF, for the FK506 Kidney Transplant Study Group Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998, 65:515.
97. Pascual J, Ortuno J Simple tacrolimus-based immunosuppressive regimens following renal transplantation: a large multicenter comparison between double and triple therapy. Spanish and Italian Tacrolimus Study Group. Transplant Proc 2002, 34:89.
98. Phelan DL, Thompson C, Henschell J, et al. Heart transplantation across preformed class I antibody using FK506. Hum Immunol 1992, 34:70.
99. Pirsch JD, Miller J, Deiorhoi MH, for the FK506 Kidney Transplant Study Group, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997, 63:977.
100. Plosker GL, Foster RH Tacrolimus: a further update of its pharmacology and therapeutic use in organ transplantation. Drugs 2000, 59:323.
101. Pohanka E, Margreiter R, Sparacino V, et al. Switch to tacrolimus-based therapy for cyclosporine-related side effects: a large, prospective European study. Transplantation 2002, 74(S):425. (abstract no. 2100).
102. Reddy KS, Stratta RJ, Shokouh-Amiri H, et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 2000, 69:49.
103. Roberti I, Reisman L, Lieberman KV, et al. Risk of steroid withdrawal in pediatric renal allograft recipients (a five-year follow up). Clin Transplant 1994, 8:405.
104. Rostaing L, Cantarovich G, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil and daclizumab induction in renal transplantation. Transplantation 2005, 79:807.
105. Sato T, Inagaki A, Uchida K, et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003, 76:1320.
106. Schnitzler MA, Lowell JA, Brennan DC: New-onset post-renal transplant hyperlipidemia with cyclosporine compared to tacrolimus. 2nd International Congress on Immunosuppression, San Diego, 2001 (abstract).
107. Schwimmer J, Zand MS Management of diabetes mellitus after solid organ transplantation. Graft 2001, 4:256.
108. Scott LJ, McKeage K, Kearn SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003, 63:1247.
109. Segoloni G, Bonomini V, Maresca MC, et al. Tacrolimus is highly effective in both dual and triple therapy regimens following renal transplantation. Spanish and Italian Tacrolimus Study Group. Transpl Int 2000, 13:S336.
110. Shapiro R, Basu A, Tan HP, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005, 200:505.
111. Shapiro R, Ellis D, Tan HP, et al. Antilymphocyte antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006, 148:813.
112. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003, 238:520.
113. Shapiro R, Jordan M, Scantlebury V, et al. A prospective, randomized trial of FK 506 in renal transplantation-a comparison between double and triple drug therapy. Clin Transplant 1994, 8:508.
114. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999, 67:411.
115. Shapiro R, Scantlebury VP, Jordan ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999, 67:299.
116. Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005, 5:874.
117. Shimizu T, Tanabe K, Tokumoto T, et al. Clinical and histological analysis of acute tacrolimus (TAC) nephrotoxicity in renal allografts. Clin Transpl 1999, 13(Suppl 1):48.
118. Solez K, Vincenti F, Filo RS Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998, 66:1736.
119. Squifflet JP, Bachman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001, 72:63.
120. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003, 361:1502.
121. Sutherland DR, Gruessner RWG, Dunn DL, et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 2001, 233:463.
122. Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506-binding protein-12 in pancreatic beta cell. Transplantation 1995, 59:1606.
123. Thompson JS Intestinal transplantation: experience in the United States. Eur J Pediatr Surg 1999, 9:271.
124. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one- and two-year outcomes. Transplantation 2006, 82:1621.
125. Todo S, Fung JJ, Starzl TE, et al. Liver, kidney and thoracic organ transplantation under FK506. Ann Surg 1990, 212:295.
126. Trimarchi HM, Truong LD, Brennan S, et al. FK-506 associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999, 67:539.
127. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus ciclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002, 17:141.
128. Van Duijnhoven EM, Boots JM, Christiaans MH, et al. Metabolic aspects of tacrolimus in renal transplantation. Minerva Urol Nefrol 2003, 55:1.
129. van Duijnhoven EM, Christiaans MH, Boots JM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002, 13:213.
130. Van Hooff JP, Christiaans MHL, Van Duijnhovern EM Tacrolimus and post-transplant diabetes mellitus in renal transplantation. Transplantation 2005, 79:1465.
131. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995, 29:404.
132. Vincenti F A decade of progress in kidney transplantation. Transplantation 2004, 77:S52.
133. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at 5 years. Transplantation 2002, 73:775.
134. Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas Study. Transplantation 2005, 80:1734.
135. Vitko S, Wlodarczyk Z, Kyllönen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 2006, 6:531.
136. Waid TH Prograf as secondary intervention versus continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes. Am J Transplant 2003, 3(Suppl 5):436. (abstract 1111).
137. Walliser P, Berizie CR, Kay JE Inhibition of murine B lymphocyte proliferation by the novel immunosuppressant drug FK506. Immunology 1989, 68:434.
138. Wasik M, Stepien-Sopniewska B, Lagodzinski Z, et al. Effect of FK506 and cyclosporine on human T and B lymphoproliferative responses. Immunopharmacology 1990, 20:57.
139. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 2005, 331:810.
140. Woeste G, Wullstein C, Dette K, et al. Tacrolimus/mycophenolate versus cyclosporine A/azathioprine after simultaneous pancreas and kidney transplantation: five-year results of a randomized study. Transplant Proc 2002, 34:1920.
141. Wong W, Venetz J-P, Tolkoff-Rubin N, et al. Immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors?. Transplantation 2005, 80:289.
142. Woodle ES, Fujisawa Corticosteroid Withdrawal Study Group A prospective, randomized, multi-center, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. Transplant Proc 2005, 37:804.
143. Woodle ES, Newell KA, Haas M, et al. Reversal of accelerated renal allograft rejection with FK506. Clin Transplant 1997, 11:2251.
144. Woodle ES, Pedrizet G, Brunt EM, et al. FK506: reversal of humorally-mediated rejection following ABO-incompatible liver transplantation. Transplant Proc 1991, 23:2992.
145. Woodle ES, Pedrizet G, Brunt EM, et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. Transplantation 1992, 54:377.
146. Woodle ES, Spargo B, Ruebe M, et al. Treatment of acute glomerular rejection with FK506. Clin Transplant 1996, 10:266.
147. Woodle ES, Thistlewaite JR, Gordon JH, for the Tacrolimus Kidney Transplant Rescue Study Group A multicenter trial of FK 506 (tacrolimus) therapy in acute refractory renal allograft rejection. Transplantation 1996, 62:594.
148. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal transplant patients. Transplantation 2003, 76:1519.